4111 Stock Overview
Engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Chi Sheng Pharma & Biotech Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$27.90 |
| 52 Week High | NT$34.90 |
| 52 Week Low | NT$24.55 |
| Beta | 0.22 |
| 1 Month Change | 2.57% |
| 3 Month Change | 6.29% |
| 1 Year Change | 4.30% |
| 3 Year Change | 21.57% |
| 5 Year Change | 13.18% |
| Change since IPO | 108.85% |
Recent News & Updates
Recent updates
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend
Apr 06
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Mar 10Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 01
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield
Jan 05Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Dec 10Shareholder Returns
| 4111 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0.9% | -0.01% | -2.1% |
| 1Y | 4.3% | -2.7% | 25.6% |
Return vs Industry: 4111 exceeded the TW Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 4111 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 4111 volatility | |
|---|---|
| 4111 Average Weekly Movement | 1.9% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4111 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4111's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | n/a | n/a | www.cscp.com.tw |
Chi Sheng Pharma & Biotech Co., Ltd engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally. Its products portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerves agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmas; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatics solutions, food products, functional drinks, skin care products, and veterinary medicinal products.
Chi Sheng Pharma & Biotech Co., Ltd Fundamentals Summary
| 4111 fundamental statistics | |
|---|---|
| Market cap | NT$1.59b |
| Earnings (TTM) | NT$71.47m |
| Revenue (TTM) | NT$1.10b |
22.2x
P/E Ratio1.4x
P/S RatioIs 4111 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4111 income statement (TTM) | |
|---|---|
| Revenue | NT$1.10b |
| Cost of Revenue | NT$744.76m |
| Gross Profit | NT$359.16m |
| Other Expenses | NT$287.69m |
| Earnings | NT$71.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.25 |
| Gross Margin | 32.53% |
| Net Profit Margin | 6.47% |
| Debt/Equity Ratio | 3.3% |
How did 4111 perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield80%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 14:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chi Sheng Pharma & Biotech Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |
| Xiaowei Huang | Masterlink Securities Corp. |